Fresh analysis reveals that individuals who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who halt conventional diet and exercise regimens.
Research printed in a major health publication points out that while obese people can lose about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users purchasing such drugs must be cognizant of the risk of rapid rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of regain implies a reversion to original mass in about one and a half years.
Weighing Approaches
The analysis, which examined dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with conventional dieting.
The team point out that individuals who lose weight through lifestyle changes alone generally have a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Fast Rebound
Nutrition scientists believe the way of the injections is key to understanding the amplified regain.
These medications imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication leads to hunger is uncontrolled, making excessive eating much more probable."
A Chronic Issue?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, considering the high risk of weight regain, the treatment is often ongoing.
This view is echoed by drug manufacturers, who state that the results "highlight the long-term character of obesity," akin to managing conditions like diabetes.
Patient Experiences
Users who have come off the medication explain a intense resurgence of appetite.
"I experienced a switch that goes on and I was suddenly ravenous," said a patient.
This challenge is worsened if patients have not established permanent dietary or behavioural changes during therapy.
Growing Use
Figures indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts stress that while these medications are effective agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing behavioural changes.
